Shattuck Labs, Inc. (STTK) es una empresa que cotiza en bolsa en el Salud sector, operando dentro de la Biotecnología industria. La empresa tiene su sede en Austin, TX, United States. El CEO actual es Taylor H. Schreiber.
STTK tiene fecha de IPO 2020-10-09, 44 empleados a tiempo completo, cotiza en el NASDAQ Global Select, una capitalización de mercado de $324.78M.
Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. It also develops SL-279252 that is in Phase 1 clinical trial in patients with advanced solid tumors and lymphoma. The company was incorporated in 2016 and is headquartered in Austin, Texas.
